Author(s):
Shradha R. Mahajan, Anjali M. Wankhade, Vivek V. Paithankar, Jugalkishor V. Vyas
Email(s):
srmahajan2002@gmail.com
DOI:
10.52711/2321-5836.2026.00046 
Address:
Shradha R. Mahajan, Anjali M. Wankhade, Vivek V. Paithankar, Jugalkishor V. Vyas
Department of Pharmacology, Vidyabharati College of Pharmacy, Amravati - 444602, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 4,
Year - 2026
ABSTRACT:
Gout is a complex metabolic and inflammatory condition associated with excessive accumulats the uric acid within body, excess uric acid may crystallize as monosodium urate (MSU), which subsequently deposits in and periarticular tissues and initiats the inflammatory cascade. This crystal deposition triggers inflammatory responses, causing joint pain, swelling, and gradual tissue deterioration. The current study evaluated the anti-gout activity of the ethanolic extract of Cleome viscosa L. (EECV) employing a experimental mouse model of gout established by MSU Crystal administration. The animals were categorized into normal control, disease control, standard drug-treated, and EECV-treated groups. The therapeutic effects were assessed through clinical parameters such as changes in body weight and paw edema, along with biochemical analysis of serum and urinary uric acid, creatinine, and blood urea nitrogen (BUN). Additionally, histopathological studies of kidney and footpad tissues using hematoxylin and eosin staining were performed to examine inflammation and tissue damage. Treatment with EECV significantly reduced paw inflammation, decreased elevated serum uric acid levels, and enhanced urinary elimination of uric acid. Improvement in renal biomarkers, including creatinine and BUN, indicated a protective effect on kidney function. Histological findings further confirmed reduced inflammatory infiltration, decreased tissue abnormalities, and improved structural integrity of affected tissues in the EECV-treated groups. The overall results suggest that Cleome viscosa exhibits considerable anti-gout activity, potentially due to its uric acid-lowering, anti-inflammatory, and kidney-protective effects, indicating its potential usefulness as a plant-based therapeutic approach for gout and hyperuricemia.
Cite this article:
Shradha R. Mahajan, Anjali M. Wankhade, Vivek V. Paithankar, Jugalkishor V. Vyas. Anti-gout effect of Cleome viscosa in combination of Monosodium Urate Injection and High Fat Diet Feeding in Experimental Animal. Research Journal of Pharmacology and Pharmacodynamics. 2026;18(4):341-8. doi: 10.52711/2321-5836.2026.00046
Cite(Electronic):
Shradha R. Mahajan, Anjali M. Wankhade, Vivek V. Paithankar, Jugalkishor V. Vyas. Anti-gout effect of Cleome viscosa in combination of Monosodium Urate Injection and High Fat Diet Feeding in Experimental Animal. Research Journal of Pharmacology and Pharmacodynamics. 2026;18(4):341-8. doi: 10.52711/2321-5836.2026.00046 Available on: https://rjppd.org/AbstractView.aspx?PID=2026-18-4-2
REFERENCES:
1. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016; 388(10055): 2039–2052.
2. Richette P, Doherty M, Pascual E, et al.2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1): 29–42.
3. Afzal M, Rednam M, Gujarathi R, Widrich J. Gout. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jun 23. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546606/
4. Asghari KM, Zahmatyar M, Seyedi F, Motamedi A, Zolfi M, Alamdary SJ, et al. Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review. BMC Musculoskelet Disord [Internet]. 2024 Dec 19 [cited 2026 Apr 16]; 25(1): 1047.
5. Safiri S, et al. Global, regional and national burden of gout, 1990–2017.Arthritis Rheumatol. 2020; 72(11): 1916–1927.
6. Cha Y, Lee J, Choy W, Lee JS, Lee HH, Chae DS. Pathophysiology and treatment of gout arthritis; including gout arthritis of hip joint: A literature review. Hip Pelvis. 2024; 36(1): 1–11. doi:10.5371/hp.2024.36.1.1
7. Martinon F, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440: 237–241.
8. Joosten LAB, Netea MG. Molecular pathogenesis of gout. Nat Rev Rheumatol. 2010; 6: 30–38.
9. Buvana C, Sumathy A, Sukumar M. In silico identification of potential xanthine oxidase inhibitors for the treatment of gout and cardiovascular disease. Asian J Res Chem. 2013; 6(11): 1049-1053.
10. Clebak KT, Morrison A, Croad JR. Gout: Rapid Evidence Review. Am Fam Physician. 2020; 102(9): 533–538.
11. Khanna D, Fitzgerald JD, Khanna PP, et al.2012 American College of Rheumatology guidelines for management of gout. Arthritis Care Res (Hoboken). 2012; 64(10): 1431–1446.
12. Friedman JE, Dallal RM, Lord JL. Gouty attacks occur frequently in postoperative gastric bypasspatients. Surg. [Multicenter Study]. 2008 Jan-Feb; 4(1): 11–13.
13. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol. 2011 Mar; 23(2): 192-202. doi: 10.1097/BOR.0b013e3283438e13.
14. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016; 388(10055): 2039–2052.
15. Shekelle PG, Newberry SJ, FitzGerald JD, et al. Management of gout: a systematic review in support of an American College of Physicians clinical practice guideline. Ann Intern Med. 2017; 166(1): 37-51
16. Hainer BL, Matheson E, Wilkes RT. Diagnosis, treatment, and prevention of gout. Am Fam Physician. 2014;90(12):831-836. Accessed July 27, 2020. https://aafp.org/afp/2014/1215/p831.html
17. Janssens HJEM, Janssen M, van de Lisdonk EH, et al. Use of oral pred-nisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008; 371(9627): 1854-1860.
18. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010; 62(4): 1060-1068.
19. Allopurinol 300mg tablets [package insert]. Accord Healthcare Limited. Updated September 2, 2020. Accessed September 16, 2020. https://www.medicines.org.uk/emc/product/6006/smpc#gref
20. White WB, Saag KG, Becker MA, et al.; CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018; 378(13): 1200-1210.
21. Lin X, Shao T, Huang L, Wen X, Wang M. Quercetin inhibits xanthine oxidase and reduces hyperuricemia in animal models. Phytother Res. 2020; 34(4): 905–912.
22. Li R, Yu K, Li C. Apigenin inhibits xanthine oxidase activity and reduces uric acid levels in hyperuricemic mice. Biomed Pharmacother. 2020; 127: 110151.
23. Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006; 8(Suppl 1): S1.
24. Poonia L, Singh GK, Nagori BP. Anti-ulcer activity of Cleome viscosa Linn. against gastric ulcer in rats. Res J Pharmacogn Phytochem. 2013; 5(3): 115-118.
25. Lakshmi V, Mishra SK. Bioactive compounds and pharmacological activities of Cleome viscosa: a review. J Ethnopharmacol. 2021; 268: 113567.
26. Lenkalapally M, Sudhakar K, Takkadpelliwar S, Nagarjuna M, Gowrishankar NL. A review on medicinal uses and pharmacological effects of Cleome viscosa. Res J Pharmacogn Phytochem. 2012; 4(1): 44-48.
27. Lenkalapally M, Cheruku S, Koppula S, Sandhi S, Mandapu N, Gowrishankar NL. Helmintholytic activity of the methanolic and aqueous extract of seeds of Cleome viscosa. Res J Pharmacol Pharmacodyn. 2012; 4(5): 259-262.
28. Sheeba Rani M, Raja Sreekanth M, Emmanuel S. Evaluation of the Wound-Healing Activity of Methanolic Extract of Cleome Viscosa Linn. Research J. Pharm. and Tech. 2011; 4(3): 441-445.
29. Andhale NS, Bhosale MS, Aher HS. Review on Cleome viscosa Linn. plant with their various biological and pharmacological activities. Asian J Res Pharm Sci. 2024; 14(2): 171-176. doi:10.52711/2231-5659.2024.00030.
30. Singh A, Sharma P. Anti-inflammatory and antioxidant activity of Cleome viscosa in experimental models. Biomed Pharmacother. 2022; 145: 112398.
31. Reddy NS, Kumar R. Cardioprotective effect of Cleome viscosa extract in diabetic rats. Asian Pac J Trop Biomed. 2024; 14(11): 450–458.
32. Gupta R, Verma N. Flavonoid glycosides from Cleome viscosa and their anti-inflammatory activity. Org Med Chem Lett. 2012; 2: 19.
33. Sanghavi MN, Barhate SD, Gopal SR, Ingale PA, Jain KV. A review on herbal approaches to gout treatment. Asian J Res Pharm Sci. 2025; 15(4): 405-408. doi:10.52711/2231-5659.2025.00061.
34. Priyanka Sahu, Sayanti Gupta, Monideepa Banerjee, Charles Lekhya Priya, Kokati Venkata Bhaskara Rao. Phytochemical Composition, Antimicrobial, Hemolytic activity and HPLC analysis of Ethanolic Extract of Cleome viscosa Linn. Stems. Research J. Pharm. and Tech. 2014; 7(10): 1140-1144.
35. Harborne JB. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. 3rd ed. New Delhi: Springer; 1998.
36. Sawant P, Ingle N, Belavale A, Shinde A, Gunjal AA, Kakade RT. Advanced extraction techniques for herbal drugs: a comprehensive review. Res J Pharmacogn Phytochem. 2025; 17(3): 229-234. doi:10.52711/0975-4385.2025.00037
37. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. 49th ed. Pune: Nirali Prakashan; 2014.
38. Organisation for Economic Co-operation and Development. OECD Guidelines for the Testing of Chemicals. Section 4: Health Effects. Test No. 423: Acute Oral Toxicity – Acute Toxic Class Method. Paris: OECD; 2001.
39. Hao G, Xu X, Song J, Xu K, Zhang J. Lipidomics analysis facilitate insight into the molecular mechanisms of urate nephropathy in a gout model induced by combination of MSU crystals injection and high-fat diet feeding. Front Mol Biosci. 2023; 10: 1190683. doi:10.3389/fmolb.2023.